Analysts Expect Inogen Inc (INGN) Will Post Earnings of $0.29 Per Share

Equities analysts expect Inogen Inc (NASDAQ:INGN) to post earnings of $0.29 per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Inogen’s earnings, with the lowest EPS estimate coming in at $0.17 and the highest estimate coming in at $0.39. Inogen posted earnings of $0.48 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 39.6%. The firm is expected to issue its next earnings report on Monday, April 29th.

According to Zacks, analysts expect that Inogen will report full year earnings of $1.91 per share for the current financial year, with EPS estimates ranging from $1.80 to $2.16. For the next year, analysts expect that the company will post earnings of $2.32 per share, with EPS estimates ranging from $2.03 to $2.59. Zacks’ earnings per share averages are an average based on a survey of research firms that follow Inogen.

Inogen (NASDAQ:INGN) last released its quarterly earnings data on Tuesday, February 26th. The medical technology company reported $0.44 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.19. Inogen had a return on equity of 18.60% and a net margin of 14.48%. The company had revenue of $86.50 million during the quarter, compared to the consensus estimate of $82.06 million. During the same quarter in the prior year, the firm posted ($0.03) earnings per share. The firm’s revenue was up 35.6% compared to the same quarter last year.

Several research analysts have recently issued reports on INGN shares. Zacks Investment Research downgraded Inogen from a “buy” rating to a “hold” rating in a research note on Thursday, February 7th. BidaskClub downgraded Inogen from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. ValuEngine downgraded Inogen from a “hold” rating to a “sell” rating in a research note on Thursday, February 28th. JPMorgan Chase & Co. lowered their price objective on Inogen to $175.00 and set an “overweight” rating for the company in a research note on Wednesday, February 27th. Finally, Piper Jaffray Companies lowered their price objective on Inogen from $290.00 to $185.00 and set an “overweight” rating for the company in a research note on Wednesday, February 27th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $189.00.

Inogen stock opened at $86.22 on Friday. Inogen has a 1 year low of $77.14 and a 1 year high of $287.79. The company has a market capitalization of $1.89 billion, a PE ratio of 37.49, a PEG ratio of 2.88 and a beta of 1.48.

Hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA raised its position in Inogen by 1,052.1% in the 1st quarter. BNP Paribas Arbitrage SA now owns 3,756 shares of the medical technology company’s stock valued at $358,000 after buying an additional 3,430 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its position in Inogen by 4.7% in the 1st quarter. Los Angeles Capital Management & Equity Research Inc. now owns 17,412 shares of the medical technology company’s stock valued at $1,661,000 after buying an additional 780 shares during the last quarter. Virginia Retirement Systems ET AL raised its position in Inogen by 27.3% in the 1st quarter. Virginia Retirement Systems ET AL now owns 9,800 shares of the medical technology company’s stock valued at $935,000 after buying an additional 2,100 shares during the last quarter. Redmond Asset Management LLC raised its position in Inogen by 1.6% in the 1st quarter. Redmond Asset Management LLC now owns 22,273 shares of the medical technology company’s stock valued at $2,124,000 after buying an additional 341 shares during the last quarter. Finally, Chicago Capital LLC raised its position in Inogen by 66.1% in the 1st quarter. Chicago Capital LLC now owns 222,235 shares of the medical technology company’s stock valued at $21,195,000 after buying an additional 88,449 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

See Also: Trading Strategy Examples and Plans

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.